NASDAQ:IMNN Imunon (IMNN) Stock Price, News & Analysis $0.78 -0.05 (-6.06%) (As of 11/12/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends About Imunon Stock (NASDAQ:IMNN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Imunon alerts:Sign Up Key Stats Today's Range$0.76▼$0.8450-Day Range$0.80▼$1.1452-Week Range$0.48▼$3.65Volume440,248 shsAverage Volume980,037 shsMarket Capitalization$46.56 millionP/E RatioN/ADividend YieldN/APrice Target$12.00Consensus RatingStrong Buy Company OverviewImunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.Read More… Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…Get Your Free Gold Guide Imunon Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks68th Percentile Overall ScoreIMNN MarketRank™: Imunon scored higher than 68% of companies evaluated by MarketBeat, and ranked 224th out of 977 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingStrong Buy Consensus RatingImunon has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageImunon has only been the subject of 2 research reports in the past 90 days.Read more about Imunon's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Imunon are expected to grow in the coming year, from ($1.71) to ($0.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Imunon is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Imunon is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImunon has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Imunon's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.52% of the float of Imunon has been sold short.Short Interest Ratio / Days to CoverImunon has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Imunon has recently increased by 43.87%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImunon does not currently pay a dividend.Dividend GrowthImunon does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.52% of the float of Imunon has been sold short.Short Interest Ratio / Days to CoverImunon has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Imunon has recently increased by 43.87%, indicating that investor sentiment is decreasing significantly. News and Social Media2.4 / 5News Sentiment0.39 News SentimentImunon has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Imunon this week, compared to 1 article on an average week.Search Interest3 people have searched for IMNN on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Imunon to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Imunon insiders have bought more of their company's stock than they have sold. Specifically, they have bought $24,500.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 5.00% of the stock of Imunon is held by insiders.Percentage Held by InstitutionsOnly 4.47% of the stock of Imunon is held by institutions.Read more about Imunon's insider trading history. Receive IMNN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Imunon and its competitors with MarketBeat's FREE daily newsletter. Email Address IMNN Stock News HeadlinesAnalysts Set Expectations for Imunon Q1 EarningsNovember 12 at 3:25 AM | americanbankingnews.comIMNN: Meeting with FDA in Preparation for Phase 3 Ovarian Cancer TrialNovember 11 at 1:01 PM | finance.yahoo.comTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…November 12, 2024 | Colonial Metals (Ad)Imunon Inc (IMNN) Q3 2024 Earnings Call Highlights: Promising Clinical Advances Amid Financial ...November 8, 2024 | finance.yahoo.comImunon presents data from Phase 2 OVATION 2 clinical trialNovember 7, 2024 | markets.businessinsider.comImunon, Inc. (IMNN) Q3 2024 Earnings Call TranscriptNovember 7, 2024 | seekingalpha.comImunon Announces Positive Data From Phase 2 Trial Of IMNN-001 In Advanced Ovarian Cancer, Stock DownNovember 7, 2024 | markets.businessinsider.comIMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual MeetingNovember 7, 2024 | globenewswire.comSee More Headlines IMNN Stock Analysis - Frequently Asked Questions How have IMNN shares performed this year? Imunon's stock was trading at $0.68 at the beginning of 2024. Since then, IMNN shares have increased by 12.6% and is now trading at $0.7660. View the best growth stocks for 2024 here. How were Imunon's earnings last quarter? Imunon, Inc. (NASDAQ:IMNN) posted its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.51) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.04. How do I buy shares of Imunon? Shares of IMNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Imunon own? Based on aggregate information from My MarketBeat watchlists, some other companies that Imunon investors own include Meta Platforms (META), Advanced Micro Devices (AMD), Energy Transfer (ET), NVIDIA (NVDA), AT&T (T), AbbVie (ABBV) and Broadcom (AVGO). Company Calendar Last Earnings8/14/2024Today11/12/2024Fiscal Year End12/31/2024Next Earnings (Estimated)3/27/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IMNN CUSIPN/A CIK749647 Webwww.imunon.com Phone(609) 896-9100Fax609-896-2200Employees33Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$12.00 Low Stock Price Target$12.00 Potential Upside/Downside+1,363.4%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,510,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-227.68% Return on Assets-127.04% Debt Debt-to-Equity RatioN/A Current Ratio1.51 Quick Ratio1.51 Sales & Book Value Annual Sales$500,000.00 Price / Sales98.49 Cash FlowN/A Price / Cash FlowN/A Book Value$1.42 per share Price / Book0.58Miscellaneous Outstanding Shares60,054,000Free Float57,051,000Market Cap$49.24 million OptionableNot Optionable Beta2.14 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report This page (NASDAQ:IMNN) was last updated on 11/12/2024 by MarketBeat.com Staff From Our PartnersAI's Growing Energy Demands: The Urgent Need for Nuclear PowerAmazon is placing a massive bet on nuclear energy to power its $150 billion data center expansion. With dem...The Bull Report | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally c...Porter & Company | SponsoredCritical warning from the mountains of CarolinaNvidia CEO Jensen Huang says Big Tech will spend over $1 trillion on data centers. And that still might not...Weiss Ratings | SponsoredCrypto’s FINAL Wealth MomentBitcoin’s final bull market is here. If you missed out on the gains in 2017, or 2021… 2025 stands to be jus...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Imunon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Imunon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.